ESMO Congress Showcases New Clinical Trial Data for Cancer Treatments

At the ESMO Congress 2026, new clinical trial results and preclinical data were presented for various cancer treatments. Calidi Biotherapeutics shared preclinical findings for CLD-501, CLD-502, and CLD-401 in solid tumors, breast, and bladder cancer. Additionally, Phase 2 data for darovasertib plus crizotinib in metastatic uveal melanoma and Phase III VOLGA trial results for IMFINZI plus enfortumab vedotin in muscle-invasive bladder cancer were highlighted, indicating potential advancements in oncology.